In July 2002 the Women's Health Initiative stopped one arm of its hormone therapy trial, and the coverage that followed cut hormone therapy prescribing by more than half within a year. Two decades of reanalysis have substantially revised that reading, but the original headlines still shape how many women, and many clinicians, think about HRT.
What the trial actually studied
The WHI enrolled women with an average age of 63, more than a decade past menopause on average, and tested two specific formulations: conjugated equine estrogens and medroxyprogesterone acetate, a synthetic progestin. It was designed to test whether hormone therapy prevented chronic disease in older women, not whether it safely relieved symptoms in women in their early fifties. Most women seeking HRT today do not look like the trial population, and most are not offered the trial's formulations.
What it found
The combined estrogen-progestin arm showed a small absolute increase in breast cancer, stroke and venous thromboembolism, alongside fewer fractures and less colorectal cancer. The estrogen-only arm, made up of women who had had a hysterectomy, showed no increase in breast cancer, and long-term follow-up has hinted at a possible reduction. That distinction was largely missing from the original coverage.
The timing hypothesis
Later age-stratified analyses found that women who started hormone therapy under 60, or within ten years of their final period, had a materially different risk profile from those who started later, including a neutral-to-favourable effect on cardiovascular outcomes. This "timing hypothesis" now underpins guidance from the Menopause Society and equivalent bodies worldwide.
Where guidance stands now
For healthy symptomatic women under 60 and within ten years of menopause, the benefits of hormone therapy generally outweigh the risks. Transdermal estrogen avoids the clot signal tied to oral routes. Micronised progesterone appears to have a more favourable profile than the synthetic progestin used in the trial. The arbitrary five-year stopping rule that followed 2002 is no longer recommended, and duration is a decision to revisit each year rather than a deadline.
What has not changed
Hormone therapy is not right for everyone. Active or recent breast cancer, unexplained vaginal bleeding, active liver disease and a history of estrogen-dependent cancer or unprovoked clotting all call for individual clinical evaluation. Risk is personal, and absolute risk, not relative risk, is the number to discuss with your clinician. Our menopause HRT guide covers how the current evidence is applied in practice.
Relative versus absolute risk
A headline saying a treatment raises a risk by 25 percent sounds alarming until you know the starting point. In the WHI combined-therapy arm, the extra breast cancer cases amounted to about one additional case per thousand women per year of use. That is a real risk and deserves honest discussion, but it is far smaller than the relative figure suggests. When weighing any treatment, ask for the absolute numbers: how many more or fewer women out of a thousand are affected, over what period.
Not all hormone therapy is the same
The trial used oral conjugated equine estrogens with a synthetic progestin. Today most women are offered transdermal estradiol, and many receive micronised progesterone instead of a synthetic progestin. Observational data suggest these choices have a more favourable profile for clots and possibly for breast cancer, although large randomised trials of these exact combinations are lacking. Route, dose and formulation all matter, which is part of why current guidance is individual rather than one-size-fits-all.
Who should still avoid hormone therapy
Reinterpreting the WHI does not mean hormones are safe for everyone. A history of breast cancer, hormone-sensitive cancers, blood clots, stroke or active liver disease generally rules out systemic therapy, and women with unexplained vaginal bleeding need that investigated first. If you are over 60 or more than ten years past menopause, the balance shifts and a careful discussion with your clinician is essential. Local vaginal estrogen is a notable exception, since very little is absorbed, and many women who cannot take systemic therapy can use it.
How to raise it with your clinician
Bring your family history, a list of your medicines and your own priorities. Ask what the benefits would be for your symptoms, what the absolute risks are for someone with your profile, and how often the decision will be reviewed. A good clinician will welcome those questions. Our article on common HRT myths and our menopausal hormone therapy guide make useful reading before your appointment.
Frequently asked questions
Did the WHI study prove HRT causes cancer?
No. It found a small increase in breast cancer with combined estrogen and a synthetic progestin in older women, and no increase with estrogen alone. The findings have been refined considerably since.
Is it safe to start HRT at 50?
For most healthy women, starting within ten years of menopause and before 60 gives a favourable balance of benefits and risks, but the decision should be individual.